Yale Scientists Identify Key Defect in Brain Tumor Cells
In a new study, Yale Cancer Center researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists. Certain malignant brain tumors and leukemias have mutations in genes known as IDH1 and IDH2. The mutations render the cancers sensitive to treatment with radiation therapy or chemotherapy, significantly increasing the survival time for patients with the mutations. To better understand this sensitivity, a cross-disciplinary team of researchers led by Yale created models of the mutation in cell cultures. The researchers tested several existing cancer drugs on the mutated cell lines. They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer. The drug caused a 50-fold increase in brain tumor cell death.
Click here to read more.
2018 Advanced Endoscopic Skull Base and Pituitary Surgery
June 1-2, 2018; New York
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
June 2-5, 2018; Denver
Complex Endoscopic Endonasal Surgery of the Skull Base
June 7-9, 2018; Pittsburgh, PA
2018 Annual Meeting of the Michigan Association of Neurological Surgeons
June 8-10, 2018; Thompsonville, MI
CARS 2018 Computer Assisted Radiology and Surgery
June 20-23, 2018; Berlin, Germany